

Correction: Evaluation of tenascin-C by tenatumomab in T-cell non-Hodgkin lymphomas identifies a new target for radioimmunotherapy

Giuseppe Gritti¹, Andrea Gianatti², Fiorella Petronzelli³, Rita De Santis³, Chiara Pavoni¹, Riccardo Lorenzo Rossi⁴, Laura Cattaneo², Luigi Giusto Spagnoli⁵, Silvia Ferrari¹, Andrea Rossi¹, Anna Maria Barbui¹ and Alessandro Rambaldi^{1,6}

¹ Hematology and Bone Marrow Transplant Units, Ospedale Papa Giovanni XXIII, Bergamo, Italy

² Pathology Unit, Ospedale Papa Giovanni XXII, Bergamo, Italy

³ Sigma Tau S.p.A. Biotech Products R and D, Pomezia, Italy

⁴ Bioinformatics, Istituto Nazionale Genetica Molecolare, Milan, Italy

⁵ Department of Biomedicine and Prevention, Università di Roma Tor Vergata, Rome, Italy

⁶ Department of Oncology and Oncohematology, Università degli Studi di Milano, Milan, Italy

Published: March 30, 2018

Copyright: Gritti et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: The online version of figure 3 has been corrected:




Figure 3: (A) Gene expression values from Iqbal et al. [25]: TNC average expression for resting cells and five type of lymphomas. (B) Gene expression values from Piccaluga et al [26]: TNC average expression for resting and activated normal CD4+ and CD8+ T cells and three types of lymphomas. All expression values are reported in relative fluorescence unit, as from original microarray datasets extracted with GEO2R functionality of the repository. (C) Differential expression values of TNC gene expression between normal tissues (resting or activated non lymphoma cells) and lymphomas from the two considered datasets relative to the TNC probes on the microarray: adjusted *p* values (BH correction), raw *p* Value and log fold change are shown for two TNC probes in both studies.

Original article: Oncotarget. 2018; 9:9766-9775. <https://doi.org/10.18632/oncotarget.23919>